1625P Multicenter, randomized, parallel group, phase II study to establish the efficacy and safety of CBP501, cisplatin, and nivolumab for ≥ third-line treatment of patients with exocrine pancreatic cancer and WBC <10,000/mm3
Thomas Enzler, Anna Nguyen, Jamal Ghazi Misleh et al. · Annals of Oncology · 2023
Cited by 3 works. doi:10.1016/j.annonc.2023.09.2574 Open-access PDF
Authors
- Thomas Enzler
- Anna Nguyen
- Jamal Ghazi Misleh
- Vivian Jean M. Cline
- Marie Johns
- Nathan M. Shumway
- Andrew Scott Paulson
- Timothy G. Larson
- Wells A. Messersmith
- Donald Richards
- Jorge M Chaves
- E. Pierce
- Mark M. Zalupski
- Vaibhav Sahai
- Taichi Kawabe
- S.A. Ruste
- A. Haun